Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Short term Debt (2016 - 2025)

Historic Short term Debt for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $1.5 million.

  • Orthopediatrics' Short term Debt rose 14503.21% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 14503.21%. This contributed to the annual value of $897000.0 for FY2024, which is 49013.16% up from last year.
  • Per Orthopediatrics' latest filing, its Short term Debt stood at $1.5 million for Q3 2025, which was up 14503.21% from $838000.0 recorded in Q2 2025.
  • Orthopediatrics' 5-year Short term Debt high stood at $1.5 million for Q3 2025, and its period low was $132000.0 during Q1 2021.
  • For the 5-year period, Orthopediatrics' Short term Debt averaged around $357684.2, with its median value being $148000.0 (2023).
  • As far as peak fluctuations go, Orthopediatrics' Short term Debt surged by 458.02% in 2021, and later surged by 49013.16% in 2024.
  • Over the past 5 years, Orthopediatrics' Short term Debt (Quarter) stood at $137000.0 in 2021, then increased by 5.11% to $144000.0 in 2022, then increased by 5.56% to $152000.0 in 2023, then soared by 490.13% to $897000.0 in 2024, then surged by 70.46% to $1.5 million in 2025.
  • Its Short term Debt was $1.5 million in Q3 2025, compared to $838000.0 in Q2 2025 and $896000.0 in Q1 2025.